Abstract
Ovarian cancer is one of the most deadly cancers with rapid proliferation and poor prognosis among patients. Therapies focusing on regulation of tumor immunity and microenvironments are developing. MiR-217 was dysregulated in cancer progress and plays important roles in tumorigenesis and metastasis. However, the role of miR-217 in regulation of macrophage polarization and its underlying molecular mechanism remain unclear. The expression of miR-217 in ovarian cancerous tissues and cell lines were assessed by qRT-PCR. And we detected the staining of CD86 and CD206 via flow-cytometry and the levels of Arg-1 and CCR2 by western-blot in order to evaluate M2 macrophage polarization. The targeting regulation of miR-217 on pro-inflammatory factor IL-6 was assessed by dual-luciferase reporter assay and western-blot. ELISA assay was used to evaluate the secretion of IL-6 and IL-10 of cells. MiR-217 was found to be downregulated in ovarian cancerous tissues and cell lines. This downregulation correlated with an increased expression of the IL-6, Arg-1, CCR2, and CD206 gene. The overexpression of miR-217 in SKOV3 cells can inhibit the polarization of macrophages towards an M2-like phenotype. We also found that IL-6 was validated to induce M2 macrophage polarization and its secretion in SKOV-3 cells was inhibited by miR-217 directly. Moreover, we revealed that miR-217 suppressed M2 macrophage polarization partly thought JAK/STAT3 signal pathway. Taken together, these findings indicate that miR-217 inhibits tumor-induced M2 macrophage polarization through targeting of IL-6 and regulation JAK3/STAT3 signaling pathway, which may provide a potential therapeutic target for treating ovarian cancer.
Similar content being viewed by others
References
Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun. 2009. Cancer statistics, 2009. CA: a Cancer Journal for Clinicians 59 (4): 225–249.
Lengyel, E. 2010. Ovarian cancer development and metastasis. The American Journal of Pathology 177 (3): 1053–1064.
Liu, Bei, J. Nash, Carolyn Runowicz, Helen Swede, Richard Stevens, and Zihai Li. 2010. Ovarian cancer immunotherapy: opportunities, progresses and challenges. Journal of Hematology& Oncology 3: 7.
Ehlen, T.G., et al. 2005. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer 15 (6): 1023–1034.
Edwards, R.P., W. Gooding, B.C. Lembersky, K. Colonello, R. Hammond, C. Paradise, C.D. Kowal, A.J. Kunschner, M. Baldisseri, J.M. Kirkwood, and R.B. Herberman. 1997. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. Journal of Clinical Oncology 15 (11): 3399–3407.
Berd, D. 2001. Autologous, hapten-modified vaccine as a treatment for human cancers. Vaccine 19 (17): 2565–2570.
Hernando, J., et al. 2002. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunology, Immunotherapy 51 (1): 45–52.
Disis, M.L., V. Goodell, K. Schiffman, and K.L. Knutson. 2004. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. Journal of Clinical Immunology 24 (5): 571–578.
Spill, F., D.S. Reynolds, R.D. Kamm, and M.H. Zaman. 2016. Impact of the physical microenvironment on tumor progression and metastasis. Current Opinion in Biotechnology 40: 41–48.
Santoiemma, P.P., and D.J. Powell. 2015. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biology & Therapy 16 (6): 807–820.
Eggermont, A., C. Robert, J.C. Soria, and L. Zitvogel. 2014. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. OncoImmunology 3 (1): e27560.
Mantovani, A., et al. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 23 (11): 549–555.
Freedman, R.S., et al. 2000. Clinical and biological effects of intraperitoneal injections of recombinant interferon-γ and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clinical Cancer Research 6 (6): 2268.
Freedman, R.S., M. Deavers, J. Liu, and E. Wang. 2004. Peritoneal inflammation - a microenvironment for epithelial ovarian cancer (EOC). Journal of Translational Medicine 2 (1): 23.
Kipps, E., D.S.P. Tan, and S.B. Kaye. 2013. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nature Reviews Cancer 13: 273–282.
Pogge von Strandmann, E., et al. 2017. Host cell interactions in ovarian cancer: pathways to therapy failure. Trends in Cancer 3 (2): 137–148.
Huang, S., et al. 2002. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. Journal of the National Cancer Institute 94: 1134–1142.
Ke, X., et al. 2016. Tumor-associated macrophages promote invasion via Toll-like receptors signaling in patients with ovarian cancer. International Immunopharmacology 40 (Supplement C): 184–195.
Duluc, D., Y. Delneste, F. Tan, M.P. Moles, L. Grimaud, J. Lenoir, L. Preisser, I. Anegon, L. Catala, N. Ifrah, P. Descamps, E. Gamelin, H. Gascan, M. Hebbar, and P. Jeannin. 2007. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 110 (13): 4319–4330.
He, L., and G.J. Hannon. 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nature Reviews. Genetics 5: 522–531.
Tong, A.W., and J. Nemunaitis. 2008. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Therapy 15: 341–355.
He, D., J. Wang, C. Zhang, B. Shan, X. Deng, B. Li, Y. Zhou, W. Chen, J. Hong, Y. Gao, Z. Chen, and C. Duan. 2015. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Molecular Cancer 14: 73.
Chen, C.-Z. 2005. MicroRNAs as oncogenes and tumor suppressors. New England Journal of Medicine 353 (17): 1768–1771.
Su, J., Q. Wang, Y. Liu, and M. Zhong. 2014. miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. Molecular and Cellular Biochemistry 392 (1–2): 289–296.
Li, J., D. Li, and W. Zhang. 2016. Tumor suppressor role of miR-217 in human epithelial ovarian cancer by targeting IGF1R. Oncology Reports 35 (3): 1671–1679.
Mezzanzanica, D. 2015. Ovarian cancer: a molecularly insidious disease. Chinese Journal of Cancer 34 (1): 1–3.
Zhao, C., W. Sun, P. Zhang, S. Ling, Y. Li, D. Zhao, J. Peng, A. Wang, Q. Li, J. Song, C. Wang, X. Xu, Z. Xu, G. Zhong, B. Han, Y.Z. Chang, and Y. Li. 2015. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biology 12 (3): 343–353.
Yin, H., X. Liang, A. Jogasuria, N.O. Davidson, and M. You. 2015. miR-217 regulates ethanol-induced hepatic inflammation by disrupting sirtuin 1-lipin-1 signaling. The American Journal of Pathology 185 (5): 1286–1296.
Wang, B., Z.L. Shen, K.W. Jiang, G. Zhao, C.Y. Wang, Y.C. Yan, Y. Yang, J.Z. Zhang, C. Shen, Z.D. Gao, Y.J. Ye, and S. Wang. 2015. MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism. BMC Cancer 15 (1): 437.
Zhao, W.-G., S.N. Yu, Z.H. Lu, Y.H. Ma, Y.M. Gu, and J. Chen. 2010. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31 (10): 1726–1733.
Bai, M., et al. 2017. MiR-217 promotes cutaneous squamous cell carcinoma progression by targeting PTRF. American Journal of Translational Research 9 (2): 647–655.
Zhang, Q., Y. Yuan, J. Cui, T. Xiao, and D. Jiang. 2015. MiR-217 promotes tumor proliferation in breast cancer via targeting DACH1. Journal of Cancer 6 (2): 184–191.
Yang, Y., H. Liu, H. Zhang, Q. Ye, J. Wang, B. Yang, L. Mao, W. Zhu, R.K. Leak, B. Xiao, B. Lu, J. Chen, and X. Hu. 2017. ST2/IL-33-dependent microglial response limits acute ischemic brain injury. The Journal of Neuroscience 37 (18): 4692–4704.
Zhang, Y., W. Sime, M. Juhas, and A. Sjölander. 2013. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. European Journal of Cancer 49 (15): 3320–3334.
Genin, M., F. Clement, A. Fattaccioli, M. Raes, and C. Michiels. 2015. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer 15: 577.
Rahal, O.M., A.R. Wolfe, P.K. Mandal, R. Larson, S. Tin, C. Jimenez, D. Zhang, J. Horton, J.M. Reuben, J.S. McMurray, and W.A. Woodward. 2018. Blocking interleukin (IL)4- and IL13-mediated phosphorylation of STAT6 (Tyr641) decreases M2 polarization of macrophages and protects against macrophage-mediated radioresistance of inflammatory breast cancer. International Journal of Radiation Oncology, Biology, Physics 100 (4): 1034–1043.
Tedesco, S., et al. 2018. Convenience versus biological significance: are PMA-differentiated THP-1 cells a reliable substitute for blood-derived macrophages when studying in vitro polarization? Frontiers in Pharmacology 9: 71.
Zhang, J., C. Wang, and H. Xu. 2017. miR-217 suppresses proliferation and promotes apoptosis in cardiac myxoma by targeting Interleukin-6. Biochemical and Biophysical Research Communications 490 (3): 713–718.
Jeannin, P., D. Duluc, and Y. Delneste. 2011. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma. Immunotherapy 3 (4 Suppl): 23–26.
Braune, J., U. Weyer, C. Hobusch, J. Mauer, J.C. Brüning, I. Bechmann, and M. Gericke. 2017. IL-6 regulates M2 polarization and local proliferation of adipose tissue macrophages in obesity. The Journal of Immunology 198 (7): 2927–2934.
Mori, T., T. Miyamoto, H. Yoshida, M. Asakawa, M. Kawasumi, T. Kobayashi, H. Morioka, K. Chiba, Y. Toyama, and A. Yoshimura. 2011. IL-1β and TNFα-initiated IL-6–STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. International Immunology 23 (11): 701–712.
Fu, X.L., W. Duan, C.Y. Su, F.Y. Mao, Y.P. Lv, Y.S. Teng, P.W. Yu, Y. Zhuang, and Y.L. Zhao. 2017. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer Immunology, Immunotherapy 66 (12): 1597–1608.
Fernando, M.R., J.L. Reyes, J. Iannuzzi, G. Leung, and D.M. McKay. 2014. The pro-inflammatory cytokine, interleukin-6, enhances the polarization of alternatively activated macrophages. PLoS One 9 (4): e94188.
Wu, Q., X. Zhou, D. Huang, Y. JI, and F. Kang. 2017. IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cellular Physiology and Biochemistry 41 (4): 1360–1369.
Acknowledgments
We would like to give our sincere gratitude to the reviewers for their constructive comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jiang, B., Zhu, SJ., Xiao, SS. et al. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer. Inflammation 42, 1517–1529 (2019). https://doi.org/10.1007/s10753-019-01004-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-019-01004-2